


Data Sheet

Product Name:	EX229
Cat. No.:	CS-0063368
CAS No.:	1219739-36-2
Molecular Formula:	C ₂₄ H ₁₈ ClN ₃ O ₃
Molecular Weight:	431.87
Target:	AMPK
Pathway:	Epigenetics; PI3K/Akt/mTOR
Solubility:	DMSO : 13 mg/mL (30.10 mM; Need ultrasonic and warming)



BIOLOGICAL ACTIVITY:

EX229, a Benzimidazole derivative, is a potent and allosteric activator of AMP-activated protein kinase (AMPK), with K_d s of 0.06 μ M, 0.06 μ M and 0.51 μ M for $\alpha 1\beta 1\gamma 1$, $\alpha 2\beta 1\gamma 1$ and $\alpha 1\beta 2\gamma 1$ in biolayer interferometry, respectively. IC₅₀ & Target: K_d : 0.06 μ M ($\alpha 1\beta 1\gamma 1$), 0.06 μ M ($\alpha 2\beta 1\gamma 1$), 0.51 μ M ($\alpha 1\beta 2\gamma 1$)^[1]. **In Vitro**: EX229 is a potent and allosteric activator of AMP-activated protein kinase (AMPK), with K_d s of 0.06 μ M, 0.06 μ M and 0.51 μ M for $\alpha 1\beta 1\gamma 1$, $\alpha 2\beta 1\gamma 1$ and $\alpha 1\beta 2\gamma 1$, respectively.^[1] Treatment of hepatocytes with EX229 (991) alone results in a slight increase in the phosphorylation of AMPK and RAPTOR only at 0.3 μ M, whereas a robust increase in ACC phosphorylation is readily observed and saturated at a concentration of 0.03 μ M EX229. AICAR or C13 alone robustly increases T172 phosphorylation of AMPK α , and when EX229 is coincubated, there is a modest additional dose-dependent increase in AMPK α phosphorylation. RAPTOR phosphorylation is modestly increased by AICAR or C13 alone, and it is dose dependently increased when incubations are carried out with EX229. EX229 also dose dependently (0.01 and 0.1 μ M) inhibits lipogenesis (34% and 63%, respectively), which is further reduced when it is coincubated with a low dose of AICAR (0.03 mM) or C13 (1 μ M). Treatment with EX229 promotes dose-dependent increases in ACC and RAPTOR phosphorylation. Similar to the observations in hepatocytes^[2].

References:

[1]. Xiao B, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017.

[2]. Bultot L, et al. Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle. Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E706-E719.

CAIndexNames:

Benzoic acid,5-[[6-chloro-5-(1-methyl-1H-indol-5-yl)-1H-benzimidazol-2-yl]oxy]-2-methyl-

SMILES:

O=C(O)C1=CC(OC2=NC3=CC(Cl)=C(C4=CC5=C(N(C)C=C5)C=C4)C=C3N2)=CC=C1C

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA